66131-77-9

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
3-Hydroxy-6-Phenylpyridine is used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals for its ability to contribute to the development of new drugs and pesticides.
Used in Neurological Disorder Treatment:
3-Hydroxy-6-Phenylpyridine is used as a potential therapeutic agent for neurological disorders due to its neuroprotective and anti-inflammatory properties, which are being studied for their potential to alleviate symptoms and improve patient outcomes.
Used in Material Science:
3-Hydroxy-6-Phenylpyridine is used in the development of novel materials, leveraging its unique chemical structure to create innovative substances with specific properties for various applications.
Used in Organic Synthesis:
3-Hydroxy-6-Phenylpyridine is used as a building block in organic synthesis, allowing for the creation of complex organic compounds with diverse applications in various industries.

InChI:InChI=1/C11H9NO/c13-10-6-7-11(12-8-10)9-4-2-1-3-5-9/h1-8,13H

Upstream product

• 55717-45-8 6-bromo-pyridin-3-ol 
• 98-80-6 phenylboronic acid 
• 106895-31-2 7-Phenyl-3-oxa-6-aza-tricyclo[3.2.0.0^2,4]hept-6-ene 
• 104704-63-4 3-benzyloxycarbonyl-4-phenyl-3-aza-7-oxatricyclo<4.1.0.0^2.5>heptane 
• 104704-57-6 2-benzyloxycarbonyl-3-phenyl-2-azabicyclo<2.2.0>hexa-5-ene 
• 113730-70-4 7-Phenyl-3-oxa-6-aza-tricyclo[3.2.0.0^2,4]heptane 
• 106895-34-5 5-Phenyl-[1,4]oxazepine 

Relevant academic research and scientific papers

COMPOUNDS FOR THE TREATMENT OF ONCOVIRUS INDUCED CANCER AND METHODS OF USE THEREOF

The pesent invention relates to compounds of formula (I) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof and their use for the prevention and treatment of oncovirus induced cancer in a subject.

INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS

The present invention relates to new inhibitors of Notch signalling pathway and its use in the treatment and/or prevention of cancers.

COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES

Disclosed herein are compounds and compositions for modulating glycolate oxidase, useful for treating oxalate-related diseases, such as hyperoxaluria, where modulating glycolate oxidase is expected to be therapeutic to a patent in need thereof. Methods of modulating glycolate oxidase activity in a human or animal subject is also provided.

The regioselective homocoupling of meta-hydroxypyridines with hypervalent iodine(iii)

The C-H homocoupling of meta-hydroxypyridines with phenyliodine(III) diacetate (PIDA) was carried out in dichloromethane at room temperature in the presence of cesium carbonate. The coupling reaction is highly regioselective with respect to the hydroxy group at the pyridine ring. Comparative control experiments with meta-alkoxypyridine suggest that the meta-hydroxy group at the pyridine ring plays a key role during the homocoupling reaction.

Contrasting Anticancer Activity of Half-Sandwich Iridium(III) Complexes Bearing Functionally Diverse 2-Phenylpyridine Ligands

We report the synthesis, characterization, and antiproliferative activity of 15 iridium(III) half-sandwich complexes of the type [(η5-Cp?)Ir(2-(R′-phenyl)-R-pyridine)Cl] bearing either an electron-donating (-OH, -CH2OH, -CH3) or electron-withdrawing (-F, -CHO, -NO2) group at various positions on the 2-phenylpyridine (2-PhPy) chelating ligand giving rise to six sets of structural isomers. The X-ray crystal structures of [(η5-Cp?)Ir(2-(2′-fluorophenyl)pyridine)Cl] (1) and [(η5-Cp?)Ir(2-(4′-fluorophenyl)pyridine)Cl] (2) exhibit the expected "piano-stool" configuration. DFT calculations showed that substituents caused only localized effects on the electrostatic potential surface of the chelating 2-PhPy ligand of the complexes. Hydrolysis of all complexes is rapid, but readily reversed by addition of NaCl. The complexes show preferential binding to 9-ethylguanine over 9-methyladenine and are active catalysts for the oxidation of NADH to NAD+. Antiproliferative activity experiments in A2780 ovarian, MCF-7 breast, A549 lung, and HCT116 colon cancer cell lines showed IC50 values ranging from 1 to 89 μM, with the most potent complex, [(η5-Cp?)Ir(2-(2′-methylphenyl)pyridine)Cl] (13) (A2780 IC50 = 1.18 μM), being 10× more active than the parent, [(η5-Cp?)Ir(2-phenylpyridine)Cl], and 2× more active than [(η5-CpxPh)Ir(2-phenylpyridine)Cl]. Intriguingly, contrasting biological activities are observed between structural isomers despite exhibiting similar chemical reactivity. For pairs of structural isomers both the nature and position of the functional group can affect the hydrophobicity of the complex. An increase in hydrophobicity resulted in enhanced cellular-iridium accumulation in A2780 ovarian cells, which generally gave rise to an increase in potency. The structural isomers [(η5-Cp?)Ir(2-(4′-fluorophenyl)pyridine)Cl] (2) and [(η5-Cp?)Ir(2-phenyl-5-fluoropyridine)Cl] (4) preferentially localized in the cytosol > membrane and particulate > nucleus > cytoskeleton. This work highlights the strong dependence of biological behavior on the nature and position of the substituent on the chelating ligand and shows how this class of organometallic anticancer complexes can be fine-tuned to increase their potency without using extended cyclopentadienyl systems. (Chemical Equation Presented).

OXAZOLOBENZIMIDAZOLE DERIVATIVES

The present invention is directed to oxazolobenzimidazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

Studies on Diazepines. XXV. Syntheses of Fully Unsaturated 1,4-Oxazepines and 1H-1,4-Diazepines Using Photochemical Valence Isomerization of Tricycloheptene Systems

3-Azatricyclo2,5>hept-3-ene derivatives prepared from pyridines via five steps were found to be useful synthons for fully unsaturated monocyclic seven-membered heterocyclic rings.Photolysis of the 7-oxa derivatives 15 resulted in valenc

Synthesis of the First Examples of Fully Unsaturated Monocyclic 1,4-Oxazepines

Photolysis of the 3-aza-7-oxatricyclo2,5>hept-3-enes (3), prepared from pyridines via five steps, results in ring expension to give the novel 1,4-oxazepines (4).